secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioNexus Gene Lab Corp (BGLC)
CIK:        0001737523
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001477932-25-008044
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia
--------------------------------------------------------------------------------

- BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
- CEO Sam Tan to serve as CEO of Fidelion; BGLC gets two board seats.
- VitaGuard MRD test detects ctDNA at 0.02% VAF, ~95% cfDNA recovery, no tissue needed.
- Exclusive ASEAN commercialization rights; initial focus on Singapore and Malaysia.
- Conditions include IP license agreement; other definitive agreements not yet executed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225008044/0001477932-25-008044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737523/000147793225008044/bglc_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-008044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer